Advances in Preventive Medicine / 2012 / Article / Fig 3

Clinical Study

A Randomized Trial Assessing the Effectiveness of Ezetimibe in South Asian Canadians with Coronary Artery Disease or Diabetes: The INFINITY Study

Figure 3

(a) Primary endpoint: percentage of patients achieving target LDL-C (<2.0 mmol/L) at 6 weeks (b) Percentage of patients achieving target LDL-C (<2.0 mmol/L) at 12 weeks.

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.